Skip to content
Valiant Laboratories logo

Valiant Laboratories

VALIANTLAB NSE
₹120.87 −2.46 (−1.99%)
P/E
41.11
View as Markdown
MCP
Close 4 Nov 2026 ₹120.87 +39.71 +48.9% 1Y
Start ₹81.16

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
0.58%
Debt to Equity
0.15
EPS (TTM)
₹2.94
Book Value
₹61.20
Market Cap
—
P/E (TTM)
41.11
P/B
1.98
ROE
−2.55%
Dividend Yield
0.00%
EBITDA
₹8.70 Cr
52W High
₹141.38
52W Low
₹49.51
Day Range
₹120.87 – ₹120.87
Volume
10,754

Peer Comparison

Healthcare › Pharmaceuticals

Valiant Laboratories peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Valiant Laboratories (this company)
₹120.8741.11₹670 Cr1.980.00%−2.55%0.58%₹306 Cr₹16 Cr
Median 8 companies₹1,587.7039.96₹1,25,337 Cr4.570.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

45 Average

Data confidence 98/100

surveillance:ASM2

Category scores

Quality
18
Poor
Returns, margins, earnings quality 22% weight
Valuation
42
Weak
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
49
Average
Solvency, leverage, coverage 9% weight
Momentum
87
Strong
Trend strength, vol-adjusted 12% weight
Ownership
57
Good
FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM2 ≤ 50).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is expected to give good quarter

Weaknesses

1
  • Company has a low return on equity of -2.15% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish658
OscillatorsNeutral252
Moving AveragesStrong Bullish406

Key readings

RSI (14)
46.22
Neutral
MACD (12,26,9)
1.71
Bearish
SMA (50)
119.53
Bullish
SMA (200)
79.37
Bullish

As of

Growth Rate

From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
3Y−10.81%
1Y+78.20%
TTM+89.44%

Net profit

Net profit growth by window
3YTurned to loss
1YLoss widened by ₹1 Cr
TTMZero base

Operating cash flow

Operating cash flow growth by window
3YTurned negative
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
3Y−7.95 pp
1Y+6.29 pp
TTM+10.82 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2023₹334 Cr
Mar 2024₹182 Cr
Mar 2025₹133 Cr
Mar 2026₹237 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2023₹29.00 Cr
Mar 2024₹0.00 Cr
Mar 2025−₹2.00 Cr
Mar 2026−₹3.00 Cr

Quarterly Results

₹ Cr
VALIANTLAB quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
51
60
41
31
19
21
35
58
47
46
52
92
115
117
Expenses
48
61
47
35
21
28
35
54
44
46
53
87
86
112
Operating Profit
4
−1
−6
−5
−2
−7
1
4
2
0
−1
5
29
5
OPM %
7%
−2.3%
−16%
−15%
−13%
−31%
1.8%
7%
5%
0.2%
−1.7%
5%
25%
4.4%
Other Income
2
3
2
2
3
3
2
−2
1
1
1
0
1
0
Interest
0
0
0
0
0
0
0
0
0
0
1
1
1
1
Depreciation
0
0
0
1
1
1
1
1
1
1
2
3
3
4
PBT
6
1
−5
−3
0
−4
2
1
2
0
−3
1
26
1
Tax %
26%
25%
−31%
−52%
219%
21%
−44%
26%
26%
25%
136%
−68%
19%
38%
Net Profit
4
1
−4
−1
−1
−5
2
1
2
0
−7
2
21
0
EPS (₹)
1.05
0.19
−0.64
−0.23
−0.09
−0.87
0.43
0.13
0.34
0.04
−1.3
0.32
3.88
—

Sep 2026: from the results filed on 2 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
VALIANTLAB profit and loss, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
334
182
133
237
306
Expenses
299
190
138
231
273
Operating Profit
35
−8
−5
6
33
OPM %
11%
−4.6%
−3.5%
2.7%
11%
Other Income
5
10
5
2
3
Interest
0
0
0
2
3
Depreciation
2
2
2
6
8
PBT
38
−1
−2
1
25
Tax %
24%
−142%
46%
525%
—
Net Profit
29
0
−2
−3
16
EPS (₹)
7.13
0.06
−0.41
−0.6
2.94
Div. Payout %
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
VALIANTLAB balance sheet, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
33
43
43
54
Reserves
68
193
191
257
Borrowings
60
77
122
46
Other Liabilities
52
29
45
107
Total Liabilities
213
343
401
464
Fixed Assets
48
50
48
227
CWIP
1
43
156
6
Investments
34
38
0
26
Other Assets
130
212
197
205
Total Assets
213
343
401
464

Cash Flow

₹ Cr
VALIANTLAB cash flow, annual, ₹ crore
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Operating
56
2
1
−10
Investing
−55
−144
−53
7
Financing
−1
152
45
2
Net Cash Flow
0
10
−7
−1
Free Cash Flow
18
−44
−112
−45
CFO/OP
185
−11
25
−147

Ratios

VALIANTLAB financial ratios, annual
Particulars Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
97
92
197
144
Inventory Days
17
22
13
84
Days Payable
62
56
128
175
Cash Conversion Cycle
52
57
82
53
Working Capital Days
70
106
156
116
ROCE %
—
−2%
−1%
1%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Valiant Laboratories insights

60 extracted metrics across FY22–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 74.94%
  • Public 19.33%
  • Others 5.58%
  • DIIs 0.08%
  • FIIs 0.07%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Valiant Laboratories

What does Valiant Laboratories Ltd do?
Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals
Where is Valiant Laboratories Ltd (VALIANTLAB) listed?
Valiant Laboratories Ltd trades as VALIANTLAB on the NSE and under code 543998 on the BSE.
Which sector does Valiant Laboratories Ltd belong to?
Valiant Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Valiant Laboratories Ltd?
Valiant Laboratories Ltd trades at a PE ratio of 41.11 as of 4 Nov 2026, on earnings per share of ₹2.94, against a book value of ₹61.2 per share.
What is the 52-week high and low of Valiant Laboratories Ltd?
Over the last 52 weeks Valiant Laboratories Ltd has traded between ₹49.51 and ₹141.38 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Valiant Laboratories Ltd?
Valiant Laboratories Ltd reported a return on equity of -2.55%. Its debt-to-equity ratio is 0.15.

Company Information

Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals

Website valiantlabs.in
Listed 6 Oct 2023
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VALIANTLAB.md for Valiant Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month